Clinical proteomics may have a spotty and troubled history, but at the Human Proteome Organization's annual conference in Toronto, the push to move proteomics from the research lab to the clinical setting was everywhere to be seen.
The most recent suit, filed last week, alleges that the researcher misrepresented and falsified data related to prostate cancer biomarkers after Onconome sponsored "millions of dollars" of research at his University of Pittsburgh and Johns Hopkins University labs to see if the technology could lead to a clinical diagnostic test for prostate cancer.
The findings, published in JAMA, suggest that the biomarkers could pinpoint cases of incipient Alzheimer's with 83 percent sensitivity and 72 percent specificity. Nevertheless, those involved say it's too early to routinely use the biomarkers in the clinic.
Individual labs have shown that multiple reaction monitoring coupled with isotope dilution mass spectrometry, or SID-MRM-MS, can be used to quantify candidate protein biomarkers in plasma, but until now no one had proven the interlaboratory reproducibility of the method or the transferability of the assays across different labs.
Included is a paper on the use of a mass spectrometry-based strategy for the absolute quantification of protein complex components, one using SISCAPA technology, and one showing that top-down proteomics can be done using CID on a q-TOF instrument.